Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Authors

Robert Motzer•António Araújo•Bernard Escudier

Published

March 21, 2018

Abstract

Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma.